인문학
사회과학
자연과학
공학
의약학
농수해양학
예술체육학
복합학
DBpia AI
AI 에이전트
AI 아이디어
AI 리더
AI 뷰어
Citeasy
크롬 서지관리 다운로드
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록·키워드
T-cell lymphoblastic leukemia/lymphoma is a highly aggressive malignancy with a 5-year overall survival rate of 35%. Mutations in the JAK/STAT pathway are the second most common mutations in T-cell lymphoblastic leukemia/lymphoma, and hyperactivation of this pathway can promote proliferation of tumor cells. Considering that artesunate and ruxolitinib can inhibit activation of the JAK/STAT pathway, this study investigated the value of these drugs in the treatment of T-lymphoblastic leukemia/lymphoma. Jurkat cells were treated with various concentrations of artesunate and/or ruxolitinib. Cell viability was detected using the CCK-8 assay, and apoptosis was detected after 48 h of treatment using flow cytometry. The effect of each drug alone and in combination was analyzed by polymerase chain reaction and western blotting assays. We also investigated the expression of relevant proteins in the JAK/STAT pathway in lymph nodes and bone marrow samples from 10 patients with T-lymphoblastic leukemia/lymphoma and two healthy controls. Artesunate and ruxolitinib, both alone and in combination, promoted apoptosis and reduced phosphorylation of JAK2 and STAT5 but did not alter mRNA or protein expression of JAK2. The drugs had a stronger inhibitory effect on growth when used in combination than when either was administered alone. Cytotoxicity assays indicated that artesunate had a potent inhibitory effect on cell viability, with IC<sub>50</sub> values of 12.86 (24 h) and 5.412 µM (48 h), whereas ruxolitinib had weaker activity (with an IC<sub>50</sub> of 30.55 µM at 24 h and 15.51 µM at 48 h). At 24 h, the total apoptotic rate was 20.75% in the control group, 30.00% in the 20 µM artesunate group, 27.24% in the 30 µM ruxolitinib group, and 43.39% in the combination group. Artesunate and ruxolitinib alone and in combination inhibited aberrant activation of the JAK/STAT pathway in T-lymphoblastic lymphoma/leukemia, supporting the value of this combination in patients with JAK/STAT protein mutations.
인공지능 문자 인식 모델을 통해 추출된 텍스트로, 일부 오타나 오류가 포함될 수 있으나 지속적으로 개선 중입니다.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
오류를 발견하셨다면 해당 부분을 드래그한 후 ' 를 통해 신고해주세요.
최근 본 자료 전체보기
